Pharmaceutical

Novo faces growth challenges despite GLP-1 receptor agonist obesity boom

The industry is seeking to scale up and satisfy demand for diabetes and obesity treatments that are now chronically in shortage.

Aug 1, 2024 - 04:00
Novo faces growth challenges despite GLP-1 receptor agonist obesity boom
The industry is seeking to scale up and satisfy demand for diabetes and obesity treatments that are now chronically in shortage.
Read the original article

Tags:

Previous Article

Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023

Next Article

Alpha Cognition’s ALPHA-1062 Becomes the Second Oral FDA-Approved Treatment for ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: U.S. appeals court upholds limits to abortion pill; ‘knock-off’ Ozempic thrives on ‘bogus’ website

STAT+: Pharmalittle: U.S. appeals court upholds limits ...

Aug 17, 2023

The first vaccine for the increasingly prevalent chikungunya virus is here

The first vaccine for the increasingly prevalent chikun...

Nov 11, 2023

Texas wants to wean trans youth off meds in a ‘safe and medically appropriate’ way. Doctors say that’s impossible

Texas wants to wean trans youth off meds in a ‘safe and...

May 27, 2023